- Home
- TRC vs HQL Comparison
TRC vs HQL Comparison
Compare TRC & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TRC | HQL |
|---|---|---|
| Founded | 1843 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Investment Managers |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 492.8M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRC | HQL |
|---|---|---|
| Price | $18.80 | $16.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 98.5K | ★ 122.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $37,830,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.72 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.04 | $10.55 |
| 52 Week High | $19.53 | $17.80 |
Technical Indicators
Market Signals| Indicator | TRC | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 69.76 | 50.08 |
| Support Level | $15.56 | $16.40 |
| Resistance Level | $19.20 | $17.51 |
| Average True Range (ATR) | 0.56 | 0.32 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 75.56 | 68.04 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.